Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SBRT plus sunitinib versus sunitinib alone for newly diagnosed metastatic renal cell carcinoma
ChiCTR1800017136Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: objective response rate. Started Aug 2018; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on ChiCTR1800017136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017136.